Dihydro-β-erythroidine is a competitive nicotinic acetylcholine receptor antagonist with moderate selectivity for the neuronal α4 receptor subunit. Dihydro-β-erythroidine have curare-like effects at peripheral nicotinic receptors, which include severe respiratory depression. Thus in vivo behavioral studies using Dihydro-β-erythroidine are limited. Dihydro-β-erythroidine antagonizes behavioral effects of nicotine in vivo. After s.c. administration, Dihydro-β-erythroidine was potent in blocking nicotine's effects except for antinociception. Intrathecal injection of Dihydro-β-erythroidine was effective in blocking the antinociceptive effect of nicotine.

Dihydro-β-erythroidine is a competitive nicotinic acetylcholine receptor antagonist with moderate selectivity for the neuronal α4 receptor subunit. Dihydro-β-erythroidine have curare-like effects at peripheral nicotinic receptors, which include severe respiratory depression. Thus in vivo behavioral studies using Dihydro-β-erythroidine are limited. Dihydro-β-erythroidine antagonizes behavioral effects of nicotine in vivo. After s.c. administration, Dihydro-β-erythroidine was potent in blocking nicotine's effects except for antinociception. Intrathecal injection of Dihydro-β-erythroidine was effective in blocking the antinociceptive effect of nicotine.